Biomarkers

Early-phase mechanistic trials test how a new drug affects disease biology and safety; results can help decide whether larger trials should follow.

If validated, an imaging-derived adipose heterogeneity biomarker could help predict who will lose response to infliximab after induction, potentially guiding earlier treatment decisions and personalized monitoring for...

The study points to three bile-acid–related genes that may be linked to inflammation in ulcerative colitis and could serve as biomarkers or targets for future research into disease mechanisms and patient stratification.

Treg/Th17 balance is a central immune mechanism implicated in IBD pathogenesis; understanding how microbes, metabolites, and tissue context control that balance could inform new biomarkers and targeted therapies.

This review summarizes human evidence that pesticides in the diet could affect the gut microbiome and may be linked to gastrointestinal outcomes including IBD; strongest consistent signals were for organochlorine...

The work aims to predict relapse and personalize herbal maintenance dosing for UC, which matters because better risk stratification and tailored management could reduce relapses and avoid unnecessary treatment changes.

Blood biomarkers that predict vedolizumab response could help patients and clinicians choose the most effective therapy sooner and avoid ineffective treatments. The study suggests LRG and MCP‑1 may differentiate...

IBD-U means no clear Crohn’s or ulcerative colitis diagnosis yet — that uncertainty can affect treatment decisions and follow-up. The review highlights tests that may help clarify diagnosis and stresses that many...

The paper identifies a gut microbiome–driven pathway (flagellin → TLR5 → IL-15 → ARA) that might link intestinal microbial changes to systemic inflammation seen in long COVID and other immune-mediated diseases,...

The report describes a novel small-molecule inhibitor (IMYX-3) targeting RAB27A to reduce neutrophil-mediated damage in ulcerative colitis models, which could point to a new therapeutic approach if later validated in...

If validated, IGFBP5 or its downstream pathway could help predict who will not respond to anti-TNF therapy and point to new targets to overcome resistance.

Quantitative, rapid stool tests could make it easier to track intestinal inflammation without central lab delays. If translated to clinical use, SERS-enhanced lateral-flow assays might allow more frequent, point-of-care...

The study points to serum protein panels and tissue expression of glypican-6 (GPC6) as potential tools to diagnose or predict intestinal strictures in Crohn disease, which could help detect fibrosis earlier and guide...

A blood test that more reliably distinguishes UC from CD could reduce diagnostic uncertainty and help guide appropriate long‑term management for people with colonic inflammatory bowel disease.

The paper suggests a new molecular link—low ALIX expression—to inflammatory cell death (pyroptosis) that might help explain mucosal inflammation in ulcerative colitis. If validated, that pathway could point to biomarkers...

If validated, blood protein signatures that appear years before symptoms could help identify people at higher risk of Crohn’s disease and point to lifestyle or dietary measures that alter early biology.

Many women with UC use hormonal contraception and worry it might worsen disease activity. This study provides evidence that HCT was not linked to more recurrent flares or higher cumulative inflammatory burden in the...

Sarcopenia (low muscle mass) was linked with worse outcomes in Crohn’s disease and, combined with fecal calprotectin and disease behaviour, formed a score that better predicted unfavourable courses. Identifying at-risk...

People with ulcerative colitis face a higher colorectal cancer risk driven in part by chronic inflammation; this review explains the molecular and immune mechanisms behind that risk and highlights biomarkers and...

This paper evaluates CAR, a simple blood‑based biomarker, in children with IBD and finds it reflects disease severity and changes over time in pediatric Crohn’s disease. That matters because reliable, easy-to-measure...

The study uses generative AI and microbiome/RNA data to search for biomarkers of intestinal fibrosis in Crohn’s disease, which could help spot scarring earlier and potentially prevent worsening complications like...

Identifies specific gut bacteria and fecal bilirubin metabolites that may link microbial loss to increased oxidative burden in IBD; suggests new biomarker candidates and targets for functional follow-up.

This project aims to improve prediction of autoimmune disease onset and immunotherapy-related autoimmunity by combining genetics and plasma proteins.

Researchers are using a new MRI-based index (ANDI) to look for early brain changes linked to Parkinson’s disease and dementia in groups at higher risk, including people with inflammatory bowel disease. If successful, the...

IBD increases risk of osteoporosis; identifying blood proteins that predict later bone loss could help flag higher-risk patients and reveal biological links between gut inflammation and bone health.

Better triage methods that combine FIT with demographics and blood biomarkers could reduce unnecessary colonoscopies while keeping sensitivity for colorectal cancer and other serious findings, which matters for...

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Infliximab. The original article is from Journal of Genetic Engineering and...

Understanding how the gut virome shapes regulatory T cells could reveal new biomarkers or therapeutic targets for IBD and related systemic immune diseases. This may help explain unexplained flares or individual...

Identifies candidate drug‑level and immune biomarker cut‑points linked with endoscopic healing in pediatric Crohn's disease, which could help guide dosing or treatment changes if validated.

Non-invasive fecal lipid markers could help differentiate UC from CD and improve diagnostic molecular profiling in IBD if validated, which may be useful for patients and clinicians seeking less-invasive diagnostic tools.

The study evaluates how well first-line 5-ASA therapy achieves modern treatment targets (endoscopic, histologic, and biomarker remission) in real-world UC patients who are clinically in remission. Patients and clinicians...

Identifies gene and microbiome patterns linked to progression from inflammation to irreversible bowel fibrosis in Crohn’s disease, which could eventually help predict who is at higher risk and inform prevention...

The T&W criteria are still used to define severe UC on admission, but relying on them alone may delay recognition of steroid non‑response and escalation decisions. Integrating biomarkers, endoscopy, and imaging can help...

Distinct circulating immune signatures could help differentiate active UC from CD and suggest disease-specific pathways that might guide future biomarkers or therapies.

If validated, blood microRNAs could become noninvasive biomarkers to help track inflammation and predict biochemical response to infliximab or vedolizumab in Crohn’s disease, complementing CRP and fecal calprotectin.

Fibrosis (irreversible bowel scarring) is a major cause of surgery in Crohn’s disease. This study points to molecular and microbiome patterns that may help predict or distinguish fibrosis from active inflammation, which...

Fibrosis (irreversible bowel scarring) is a major cause of surgery in Crohn’s disease. Identifying molecular and microbial markers tied to fibrosis could eventually help predict who’s at higher risk and guide earlier,...

The work points to measurable molecular and microbial patterns that may help distinguish treatable inflammation from progressive fibrosis and suggests AI could aid in building predictive tools from limited samples —...

The probe targets azoreductase-driven hypoxia, a mechanism linked to ulcerative colitis and other hypoxia-associated diseases; a reliable real-time imaging method could help research and eventually guide treatments.

AI tools could make objective disease assessment faster and more consistent, help detect inflammation beyond what symptoms suggest, and ultimately support more personalized treatment choices for people with Crohn’s...

The study links shared gene-expression patterns between IBD and ankylosing spondylitis and highlights STAT3 as a potential shared biomarker or therapeutic target, which could be relevant for understanding overlapping...

AI could help make IBD assessments (endoscopy, histology, imaging, biomarkers) more objective and faster, which may improve monitoring, treatment selection, and early detection of complications for people with Crohn’s...

Researchers used genetics plus single-cell sequencing and ELISA to prioritize plasma protein ratios that may causally relate to ulcerative colitis. If validated in larger studies, such biomarkers could help with...

Faecal calprotectin appears to be the best non‑invasive test among those studied for distinguishing UC from Crohn’s disease and for reflecting mucosal inflammation. Simpler blood‑based scores may help gauge systemic...

If you or a loved one follow emerging IBD treatments, this update signals a new PALI-2108 program moving into Phase 2 for ulcerative colitis and planned Phase 2 testing in Crohn’s disease, plus a company focus on...

ILCs help regulate mucosal immunity and their imbalance is linked to intestinal inflammation; understanding them may point to new biomarkers and future therapies for IBD. Clinicians and researchers may find insights...

Researchers found antisense RNA activity in gut microbes that tracks with active inflammation in IBD and with faecal calprotectin — suggesting a new microbial signal that might help understand or monitor disease...

This review pools available human and animal studies on sodium butyrate for ulcerative colitis and highlights promising signals—especially for oral microencapsulated formulations—while noting that clinical evidence is...